Horenshtein Hadar Mirit 4
4 · Silexion Therapeutics Corp · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Silexion (SLXN) CFO Mirit Horenshtein Hadar Receives 49,726 Shares
What Happened Mirit Horenshtein Hadar, Chief Financial Officer and Secretary of Silexion Therapeutics Corp (SLXN), was granted 49,726 restricted share units (RSUs) that were fully vested and immediately settled into 49,726 ordinary shares on February 20, 2026. The Form 4 reports the acquisition price as $0.00 (award/settlement), so this was a compensation award rather than an open-market purchase.
Key Details
- Transaction date: February 20, 2026; Form 4 filed February 23, 2026 (filed in a timely manner).
- Transaction type/code: Award/Grant (A) — fully vested RSUs immediately settled for underlying shares.
- Shares acquired: 49,726 ordinary shares; reported acquisition price $0.00.
- Shares owned after transaction: Not specified in the provided filing.
- Footnotes: (F2) RSUs were fully vested and immediately settled for underlying shares; grant approved by the board. (F1) Reported share counts reflect adjustments for the issuer's 1-for-9 and 1-for-15 reverse splits in Nov 2024 and Jul 2025.
- No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the filing.
Context This was a compensatory award (RSUs) settled into stock, not a market purchase or sale — common for executive compensation and not necessarily a signal of personal buying/selling intent. Because the RSUs were immediately settled, there was no option exercise or cashless sale involved; the filing simply records the issuance/settlement of shares to the officer.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-02-20+49,726→ 50,146 total
Footnotes (2)
- [F1]The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.
- [F2]The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors.